Anti-integrin therapy for multiple sclerosis

Autoimmune Diseases

Volumn 1, Issue 1, 2012, Pages

  Kawamoto, Eiji ^a   Nakahashi, Susumu ^a   Okamoto, Takayuki ^b   Imai, Hiroshi ^a   Shimaoka, Motomu ^b  

^a MIE UNIVERSITY HOSPITAL   (Japan)

^b MIE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB; PLACEBO;

CELL ADHESION; CELL HOMING; CELL INTERACTION; DRUG SURVEILLANCE PROGRAM; ENDOTHELIUM CELL; HUMAN; LEUKOCYTE; LEUKOCYTE ADHESION DEFICIENCY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RISK MANAGEMENT; TISSUE SPECIFICITY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 84872147557     PISSN: None     EISSN: 20900430     Source Type: Journal    
DOI: 10.1155/2012/357101     Document Type: Review

References (51)

1. Frohman E. M., Racke M. K., Raine C. S., Medical progress: multiple sclerosis-the plaque and its pathogenesis. New England Journal of Medicine 2006 354 9 942 955 2-s2.0-33644607018 10.1056/NEJMra052130
2. Trapp B. D., Nave K. A., Multiple sclerosis: an immune or neurodegenerative disorder? Annual Review of Neuroscience 2008 31 247 269 2-s2.0-48249139449 10.1146/annurev.neuro.30.051606.094313
3. Steinman L., A molecular trio in relapse and remission in multiple sclerosis. Nature Reviews Immunology 2009 9 6 440 447 2-s2.0-67349213676 10.1038/nri2548
4. Naci H., Fleurence R., Birt J., Duhig A., Economic burden of multiple sclerosis: a systematic review of the literature. PharmacoEconomics 2010 28 5 363 379 2-s2.0-77951442188 10.2165/11532230-000000000-00000
5. Goverman J., Autoimmune T cell responses in the central nervous system. Nature Reviews Immunology 2009 9 6 393 407 2-s2.0-67349216357 10.1038/nri2550
6. Ransohoff R. M., Natalizumab for multiple sclerosis. New England Journal of Medicine 2007 356 25 2622 2629 2-s2.0-34250779802 10.1056/NEJMct071462 (Pubitemid 46961007)
7. Luo B. H., Carman C. V., Springer T. A., Structural basis of integrin regulation and signaling. Annual Review of Immunology 2007 25 619 647 2-s2.0-34247891506 10.1146/annurev.immunol.25.022106.141618 (Pubitemid 46697919)
8. Hynes R. O., Integrins: bidirectional, allosteric signaling machines. Cell 2002 110 6 673 687 2-s2.0-0037145037 10.1016/S0092-8674(02)00971-6 (Pubitemid 35283958)
9. Askari J. A., Buckley P. A., Mould A. P., Humphries M. J., Linking integrin conformation to function. Journal of Cell Science 2009 122 2 165 170 2-s2.0-61949358716 10.1242/jcs.018556
10. Shimaoka M., Takagi J., Springer T. A., Conformational regulation of integrin structure and function. Annual Review of Biophysics and Biomolecular Structure 2002 31 485 516 2-s2.0-0036089390 10.1146/annurev.biophys.31.101101. 140922 (Pubitemid 34666842)
11. Moser M., Legate K. R., Zent R., Fässler R., The tail of integrins, talin, and kindlins. Science 2009 324 5929 895 899 2-s2.0-66149128873 10.1126/science.1163865
12. Evans R., Patzak I., Svensson L., De Filippo K., Jones K., McDowall A., Hogg N., Integrins in immunity. Journal of Cell Science 2009 122 2 215 225 2-s2.0-61949195236 10.1242/jcs.019117
13. Rose D. M., Han J., Ginsberg M. H., 4 integrins and the immune response. Immunological Reviews 2002 186 118 124 2-s2.0-0036696904 10.1034/j.1600-065X. 2002.18611.x
14. Kim C., Ye F., Ginsberg M. H., Regulation of integrin activation. Annual Review of Cell and Developmental Biology 2011 27 321 345
15. Imai Y., Shimaoka M., Kurokawa M., Essential roles of VLA-4 in the hematopoietic system. International Journal of Hematology 2010 91 4 569 575 2-s2.0-77954535224 10.1007/s12185-010-0555-3
16. Alon R., Dustin M. L., Force as a facilitator of integrin conformational changes during leukocyte arrest on blood vessels and antigen-presenting cells. Immunity 2007 26 1 17 27 2-s2.0-33846246384 10.1016/j.immuni.2007.01.002 (Pubitemid 46109349)
17. Yang J. T., Rayburn H., Hynes R. O., Cell adhesion events mediated by 4 integrins are essential in placental and cardiac development. Development 1995 121 2 549 560 2-s2.0-0028955748
18. Anderson D. C., Springer T. A., Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annual Review of Medicine 1987 38 175 194 2-s2.0-0023083976
19. Fischer A., Lisowska-Grospierre B., Anderson D. C., Springer T. A., Leukocyte adhesion deficiency: molecular basis and functional consequences. Immunodeficiency Reviews 1988 1 1 39 54 2-s2.0-0024211945 (Pubitemid 19000739)
20. Etzioni A., Defects in the leukocyte adhesion cascade. Clinical Reviews in Allergy and Immunology 2010 38 1 54 60 2-s2.0-75949125659 10.1007/s12016-009-8132-3
21. Petri B., Phillipson M., Kubes P., The physiology of leukocyte recruitment: an in vivo perspective. Journal of Immunology 2008 180 10 6439 6446 2-s2.0-45549106551
22. Luster A. D., Alon R., von Andrian U. H., Immune cell migration in inflammation: present and future therapeutic targets. Nature Immunology 2005 6 12 1182 1190 2-s2.0-30044447736 10.1038/ni1275 (Pubitemid 43045626)
23. Phillipson M., Heit B., Colarusso P., Liu L., Ballantyne C. M., Kubes P., Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. Journal of Experimental Medicine 2006 203 12 2569 2575 2-s2.0-33751525386 10.1084/jem.20060925 (Pubitemid 44833334)
24. Shulman Z., Shinder V., Klein E., Grabovsky V., Yeger O., Geron E., Montresor A., Bolomini-Vittori M., Feigelson S. W., Kirchhausen T., Laudanna C., Shakhar G., Alon R., Lymphocyte crawling and transendothelial migration require chemokine triggering of high-affinity LFA-1 integrin. Immunity 2009 30 3 384 396 2-s2.0-61949089067 10.1016/j.immuni.2008.12.020
25. Park E. J., Peixoto A., Imai Y., Goodarzi A., Cheng G., Carman C. V., Von Andrian U. H., Shimaoka M., Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes. Blood 2010 115 8 1572 1581 2-s2.0-77949884325 10.1182/blood-2009-08-237917
26. Carman C. V., Mechanisms for transcellular diapedesis: probing and pathfinding by 'invadosome-like protrusions'. Journal of Cell Science 2009 122 17 3025 3035 2-s2.0-70350351213 10.1242/jcs.047522
27. Nieminen M., Henttinen T., Merinen M., Marttila-Ichihara F., Eriksson J. E., Jalkanen S., Vimentin function in lymphocyte adhesion and transcellular migration. Nature Cell Biology 2006 8 2 156 162 2-s2.0-33645165031 10.1038/ncb1355
28. Millán J., Hewlett L., Glyn M., Toomre D., Clark P., Ridley A. J., Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains. Nature Cell Biology 2006 8 2 113 123 2-s2.0-33645162400 10.1038/ncb1356
29. Carman C. V., Sage P. T., Sciuto T. E., de la Fuente M. A., Geha R. S., Ochs H., Dvorak H. F., Dvorak A. M., Springer T. A., Transcellular diapedesis is initiated by invasive podosomes. Immunity 2007 26 6 784 797 2-s2.0-34250168972 10.1016/j.immuni.2007.04.015 (Pubitemid 46907670)
30. Proebstl D., Voisin M.-B., Woodfin A., Whiteford J., D'Acquisto F., Jones G. E., Nourshargh S., Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. Journal of Experimental Medicine 2012 209 6 1219 1234 10.1084/jem.20111622
31. Mora J. R., von Andrian U. H., T-cell homing specificity and plasticity: new concepts and future challenges. Trends in Immunology 2006 27 5 235 243 2-s2.0-33748160137 10.1016/j.it.2006.03.007 (Pubitemid 44308124)
32. Sigmundsdottir H., Butcher E. C., Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nature Immunology 2008 9 9 981 987 2-s2.0-50049106591 10.1038/ni.f.208
33. Yednock T. A., Cannon C., Fritz L. C., Sanchez-Madrid F., Steinmann L., Karin N., Prevention of experimental autoimmune encephalomyelitis by antibodies against 4 β 1 integrin. Nature 1992 356 6364 63 66 2-s2.0-0026506799 10.1038/356063a0
34. Engelhardt B., Laschinger M., Schulz M., Samulowitz U., Vestweber D., Hoch G., The development of experimental autoimmune encephalomyelitis in the mouse requires 4-integrin but not 4 β 7-integrin. Journal of Clinical Investigation 1998 102 12 2096 2105 2-s2.0-0032535368 (Pubitemid 29018816)
35. Soilu-Hänninen M., Röyttä M., Salmi A., Salonen R., Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. Journal of Neuroimmunology 1997 72 1 95 105 2-s2.0-0343924590 10.1016/S0165-5728(96)00158-0 (Pubitemid 27016157)
36. Piraino P. S., Yednock T. A., Freedman S. B., Messersmith E. K., Pleiss M. A., Vandevert C., Thorsett E. D., Karlik S. J., Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of 4 integrin. Journal of Neuroimmunology 2002 131 1-2 147 159 2-s2.0-0036789966 10.1016/S0165-5728(02)00273-4
37. Tubridy N., Behan P. O., Capildeo R., Chaudhuri A., Forbes R., Hawkins C. P., Hughes R. A. C., Palace J., Sharrack B., Swingler R., Young C., Moseley I. F., MacManus D. G., Donoghue S., Miller D. H., The effect of anti- 4 integrin antibody on brain lesion activity in MS. Neurology 1999 53 3 466 472 (Pubitemid 29382036)
38. Miller D. H., Khan O. A., Sheremata W. A., Blumhardt L. D., Rice G. P. A., Libonati M. A., Willmer-Hulme A. J., Dalton C. M., Miszkiel K. A., O'Connor P. W., A controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 2003 348 1 15 23 10.1056/NEJMoa020696 (Pubitemid 36026342)
39. Polman C. H., O'Connor P. W., Havrdova E., Hutchinson M., Kappos L., Miller D. H., Phillips J. T., Lublin F. D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M. A., Sandrock A. W., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 2006 354 9 899 910 2-s2.0-33644584352 10.1056/NEJMoa044397
40. Rudick R. A., Stuart W. H., Calabresi P. A., Confavreux C., Galetta S. L., Radue E. W., Lublin F. D., Weinstock-Guttman B., Wynn D. R., Lynn F., Panzara M. A., Sandrock A. W., Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine 2006 354 9 911 923 2-s2.0-33644608613 10.1056/NEJMoa044396
41. Langer-Gould A., Atlas S. W., Green A. J., Bollen A. W., Pelletier D., Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. New England Journal of Medicine 2005 353 4 375 381 2-s2.0-22844445230 10.1056/NEJMoa051847 (Pubitemid 41132342)
42. Kleinschmidt-DeMasters B. K., Tyler K. L., Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. New England Journal of Medicine 2005 353 4 369 374 2-s2.0-22844439662 10.1056/NEJMoa051782 (Pubitemid 41132341)
43. Van Assche G., Van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., Verbeeck J., Geboes K., Robberecht W., Rutgeerts P., Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. New England Journal of Medicine 2005 353 4 362 368 2-s2.0-22844445587 10.1056/NEJMoa051586 (Pubitemid 41132340)
44. Lindå H., Von Heijne A., Major E. O., Ryschkewitsch C., Berg J., Olsson T., Martin C., Progressive multifocal leukoencephalopathy after natalizumab monotherapy. New England Journal of Medicine 2009 361 11 1081 1087 2-s2.0-70149111495 10.1056/NEJMoa0810316
45. Carson K. R., Focosi D., Major E. O., Petrini M., Richey E. A., West D. P., Bennett C. L., Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. The Lancet Oncology 2009 10 8 816 824 2-s2.0-67651158993 10.1016/S1470-2045(09)70161-5
46. Major E. O., Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annual Review of Medicine 2010 61 35 47 2-s2.0-77949375380 10.1146/annurev.med.080708.082655
47. Huggett B., How Tysabri survived. Nature Biotechnology 2009 27 11 986 2-s2.0-70449336507 10.1038/nbt1109-986
48. Bloomgren G., Richman S., Hotermans C., Subramanyam M., Goelz S., Natarajan A., Lee S., Plavina T., Scanlon J. V., Sandrock A., Bozic C., Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New England Journal of Medicine 2012 366 20 1870 1880 10.1056/NEJMoa1107829
49. Foley J., Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis. The American journal of managed care 2010 16 6, supplement S178 S183 2-s2.0-77958136697
50. Rudick R., Polman C., Clifford D., Miller D., Steinman L., Natalizumab: bench to bedside and beyond. Archives of Neurology. In press
51. Miller D. H., Weber T., Grove R., Wardell C., Horrigan J., Graff O., Atkinson G., Yousry T., MacManus D., Montalban X., Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2012 11 2 131 139 10.1016/S1474-4422(11)70299-X